PL2983706T3 - Zastosowanie domen tłumiących układ immunologiczny jako leków - Google Patents

Zastosowanie domen tłumiących układ immunologiczny jako leków

Info

Publication number
PL2983706T3
PL2983706T3 PL14722538T PL14722538T PL2983706T3 PL 2983706 T3 PL2983706 T3 PL 2983706T3 PL 14722538 T PL14722538 T PL 14722538T PL 14722538 T PL14722538 T PL 14722538T PL 2983706 T3 PL2983706 T3 PL 2983706T3
Authority
PL
Poland
Prior art keywords
medicaments
immune suppressive
domains
suppressive domains
immune
Prior art date
Application number
PL14722538T
Other languages
English (en)
Inventor
Shervin Bahrami
Mogens RYTTERGÅRD DUCH
Christian KANSTRUP HOLM
Magdalena Janina LASKA
Original Assignee
Isd Immunotech Aps
Aarhus Universitet (University Of Aarhus)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isd Immunotech Aps, Aarhus Universitet (University Of Aarhus) filed Critical Isd Immunotech Aps
Publication of PL2983706T3 publication Critical patent/PL2983706T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14722538T 2013-04-10 2014-04-10 Zastosowanie domen tłumiących układ immunologiczny jako leków PL2983706T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201370200 2013-04-10
DKPA201370202 2013-04-10
DKPA201370204 2013-04-11
EP14722538.7A EP2983706B1 (en) 2013-04-10 2014-04-10 Use of immune suppressive domains as medicaments
PCT/DK2014/050091 WO2014166502A2 (en) 2013-04-10 2014-04-10 Use of immune suppressive domains as medicaments

Publications (1)

Publication Number Publication Date
PL2983706T3 true PL2983706T3 (pl) 2021-11-02

Family

ID=50685719

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14722538T PL2983706T3 (pl) 2013-04-10 2014-04-10 Zastosowanie domen tłumiących układ immunologiczny jako leków

Country Status (9)

Country Link
US (2) US11484567B2 (pl)
EP (2) EP3906931A3 (pl)
DK (1) DK2983706T3 (pl)
ES (1) ES2877553T3 (pl)
HU (1) HUE054698T2 (pl)
PL (1) PL2983706T3 (pl)
PT (1) PT2983706T (pl)
SI (1) SI2983706T1 (pl)
WO (1) WO2014166502A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
EP3497119A1 (en) 2016-08-09 2019-06-19 Aarhus Universitet Modulation of ifi16 and sting activity
US11352421B2 (en) 2018-12-11 2022-06-07 Rush University Medical Center Treatment for adverse immune reaction to metal implant debris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148621A0 (en) * 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
ATE495196T1 (de) * 2003-12-18 2011-01-15 Angeletti P Ist Richerche Bio Verfahren zur herstellung eines peptid-träger- konjugats mit hoher immunogenizität
JP2007536253A (ja) * 2004-05-04 2007-12-13 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 細胞内への核酸の送達を増強し、細胞中の標的遺伝子の発現を修飾するための組成物及び方法
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
CA2628113A1 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2009033660A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of octreotide as a therapeutic agent
CN101918566A (zh) * 2007-11-22 2010-12-15 Biontex实验室有限公司 通过影响先天性免疫系统改进非病毒输送系统的转染结果
MX374075B (es) * 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses

Also Published As

Publication number Publication date
ES2877553T3 (es) 2021-11-17
EP2983706A2 (en) 2016-02-17
SI2983706T1 (sl) 2021-08-31
HUE054698T2 (hu) 2021-09-28
US11484567B2 (en) 2022-11-01
EP2983706B1 (en) 2021-05-19
EP3906931A2 (en) 2021-11-10
US20230141663A1 (en) 2023-05-11
DK2983706T3 (en) 2021-06-14
WO2014166502A2 (en) 2014-10-16
WO2014166502A3 (en) 2014-12-18
EP3906931A3 (en) 2022-02-23
US20160175387A1 (en) 2016-06-23
PT2983706T (pt) 2021-06-18

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
IL241101A0 (en) Medicinal uses of empagliflozin
IL241102B (en) Medicinal uses of empagliflozin
IL243536A0 (en) Medical uses of cd38 agonists
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
PL2981271T3 (pl) Zastosowania terapeutyczne empagliflozyny
SG11201603028SA (en) Purification of proteins
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
ZA201604502B (en) Use of benzimidazole-proline derivatives
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
PT3071247T (pt) Dispositivo para a construção de pele
ZA201602831B (en) Use of lactones
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
DK2983706T3 (en) Use of Immune Suppressive Domains as Medicaments
TWM475834U (en) Improved structure of glove
TWM475821U (en) Structure of mosquito-catch
PL3071575T3 (pl) Wytwarzanie normorfinanów
TWM475359U (en) Improved structure of album
HRP20190035T1 (hr) Obrada krutina s visokim sadržajem sumpora
GB201304608D0 (en) BenTime of Yisrael operable arrangement
TWM475524U (en) Structure of rivet-pulling
TWM476537U (en) Structure of kettle